中国肿瘤生物治疗杂志2018，Vol.25Issue(1)：1-8,8.DOI:10.3872/j.issn.1007-385x.2018.01.001
NK细胞肿瘤免疫治疗技术的挑战
Challenges on NK cell cancer immunotherapy
摘要
Abstract
Nature killer(NK) cells possess an great potential on cancer immunotherapy without long term potential adverse events and unpredictable risks due to its biological characteristics,including MHC-independent recognition and rapid killing mechanisms to the target cell,using allogenic donor cells without GVHD,short circulation life span and low CRS risks.Although NK cells from PBMC shown an great tumor killing activities and less safety concerns than from other sources including stem cell and NK cell lines,but an efficient and safer protocols for NK cell expansion from PBMC still need to be improved.NK cell is considered as a great vector for chimera antigen receptors (CARs),however low efficiency of DNA transfection on primary NK cells is still the technically bottle neck for CAR-NK application.Clinical trails with NK cell therapy have shown encouraging efficacies on hematologic malignancy,but inconsistent on solid tumors because the NK cells that were produced from variety source cells and different protocols are differ from phenotype and function.In overall,significant progresses have made on NK cell immunotherapy in recent years,but challenges still ahead in term of manufacture and efficacy.关键词
自然杀伤细胞/肿瘤免疫治疗/过继转输/回输/NK细胞扩增Key words
nature killer cell/cancer immunotherapy/adoptive transfer/infusion/NK cell expansion分类
医药卫生引用本文复制引用
方芳,肖卫华,田志刚..NK细胞肿瘤免疫治疗技术的挑战[J].中国肿瘤生物治疗杂志,2018,25(1):1-8,8.基金项目
国家重点基础研究发展计划(973计划)资助项目(No.2016YFC1303503) （973计划）
中国科学院战略性先导科技专项(B类)资助(No.XDPB0303) （B类）
安徽省科技厅重大专项资助(No.17030801024).Project supported by the National Key Basic Research Program (973Program) of China (No.2016YFC1303503),the Strategic Priority Research Program of the Chinese Academy of Sciences (No.XDPB0303),and the Major Project from the Science and Technology Department of Anhui Province (No.17030801024) （No.17030801024）
